3034 results for "Psilocybin"
Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol
OpenAlex – October 07, 2024
Summary
Psilocybin shows significant promise in mental health, driving a surge in psychedelics and drug studies. To understand this impact, a new protocol outlines a scoping review of existing qualitative research on psilocybin-assisted psychotherapy. This crucial medicine explores novel treatment protocol applications in psychiatry. Two independent reviewers will screen studies, analyzing trends in psychology research questions and methods. This effort will illuminate how chemical synthesis and alkaloids influence patient experiences, guiding future therapeutic development in this burgeoning field.
Abstract
IntroductionThere has been a surge in research into psilocybin-assisted psychotherapy over the past decade, with many studies indicating this may b...
Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial
PLoS Medicine – September 19, 2025
Summary
Psychedelics and Drug Studies reveal a powerful combination for healthcare burnout. Combining psilocybin-assisted therapy with an 8-week Mindfulness-Based Stress Reduction program significantly reduced depressive symptoms in frontline physicians and nurses. Among 25 participants, the psilocybin group showed a 4.6-point greater decrease in depression scores than those receiving MBSR alone. This promising finding, part of Complementary and Alternative Medicine Studies, suggests a safe, effective approach for a population struggling with pandemic-related distress, though effects waned by six months.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis
Journal of Humanistic Psychology – June 12, 2021
Summary
Psilocybin-assisted group psychotherapy profoundly shifted how individuals processed trauma. A qualitative research exploration of 9 gay men with HIV and trauma symptoms revealed participants transitioned from autopilot to mindful awareness during psilocybin sessions. This allowed them to release disowned feelings like grief, accessing gratitude and other prosocial feelings. Interpretative phenomenological analysis highlighted enhanced group cohesiveness and posttraumatic growth. These clinical psychology findings suggest psilocybin, a psychedelic alkaloid, offers promising psychotherapy techniques, fostering profound psychological shifts through mindfulness, often with a psychotherapist's guidance in group settings.
Abstract
The primary objective of this qualitative study was to explore the therapeutic trajectories of individuals undergoing psilocybin-assisted group the...
Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs
Psychopharmacology – April 23, 2025
Summary
Psilocybin, a potent hallucinogen, significantly reduces depression, demonstrating a moderate effect (g = 0.62). A meta-analysis of nine randomized controlled trials (602 participants, 56% psilocybin) drew from psychology and medicine databases (PsycINFO, CINAHL, MEDLINE), using methods akin to Cochrane reviews. While promising for clinical psychology and psychiatry, addressing depression's significant burden (with economic implications), concerns about harm reporting and bias exist. The precise neurotransmitter receptor influence on behavior is unclear. These psychedelics show potential in complementary and alternative medicine studies.
Abstract
Abstract Rationale Psilocybin is a potentially paradigm-shifting depression intervention. We conducted a systematic review and meta-analysis of psi...
Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders
OpenAlex – December 18, 2025
Summary
Imagine a therapy where a single psychedelic session could unlock rigid personality patterns. Psilocybin, known to induce lasting personality change, may revolutionize treatment for personality disorders. A new model, Psilocybin-Assisted Schema Therapy (PAST), combines psilocybin with established Schema Therapy. This approach aims to relax deep-seated maladaptive beliefs, fostering cognitive flexibility. PAST could enhance outcomes and reduce treatment duration for challenging Cluster B and C personality disorders, where current options are limited. This framework outlines future studies on its potential.
Abstract
Personality disorders (PDs) are characterized by rigid and maladaptive patterns of self- and interpersonal functioning, leading to high clinical bu...
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial
OpenAlex – January 01, 2025
Summary
Frontline healthcare professionals facing burnout and depressive symptoms from COVID-19 experienced superior stress reduction with group psilocybin-assisted psychotherapy. A randomized controlled trial of 25 physicians and nurses demonstrated that combining 25mg psilocybin with Mindfulness-based stress reduction (MBSR) significantly improved depressive symptoms and burnout compared to MBSR alone. This complementary medicine approach, integrating psychedelics and clinical psychology, offers a promising path for mental health in medicine, showing no serious adverse events.
Abstract
Abstract Objective This clinical trial sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR for frontline healthcare provi...
Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
Scientific reports – July 17, 2024
Summary
Psilocybin-assisted psychotherapy shows promising results for cancer patients experiencing end-of-life distress. In a groundbreaking Canadian program, eight palliative care patients received legal access to psychedelics for therapeutic use. After treatment, participants reported significant improvements in anxiety, depression, pain, and quality of life. While most found the experience meaningful, careful screening remains vital.
Abstract
Recent clinical trials have found that the serotonergic psychedelic psilocybin effectively alleviates anxiodepressive symptoms in patients with lif...
Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress
Journal of Humanistic Psychology – June 14, 2017
Summary
Psilocybin-assisted psychotherapy offers profound benefits for cancer patients experiencing anxiety, significantly improving quality of life and spirituality. Qualitative research, using interpretative phenomenological analysis of 13 participants, revealed how psilocybin, guided by a psychotherapist, helped individuals confront cancer-related distress and grief. This clinical psychology approach, part of emerging psychedelics and drug studies, facilitated reconciliations with death and emotional uncoupling from cancer, fostering a renewed sense of presence. Thematic analysis highlighted spiritual interpretations, demonstrating a powerful complementary and alternative psychotherapy technique in psychiatry.
Abstract
Recent randomized controlled trials of psilocybin-assisted psychotherapy for patients with cancer suggest that this treatment results in large-magn...
Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.
Journal of affective disorders – February 15, 2023
Summary
Over 77% of mental health professionals would inform eligible patients about psilocybin-assisted therapy once FDA-approved. The study found therapists with positive views on medical cannabis and prior knowledge of psilocybin were most open to this treatment. Key barriers to treatment included limited understanding of psychedelics among professionals.
Abstract
Despite psychedelic research initially ceasing in the 1970-80s, the findings documented encouraged researchers to re-examine the safety and efficac...
Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.
Scientific reports – April 17, 2024
Summary
Psilocybin therapy combined with specialized psychotherapy shows promising results in treating major depression by enhancing mental adaptability. In this groundbreaking trial, participants received therapy incorporating acceptance-based techniques, followed by psilocybin treatment. Results showed significant improvements in mental flexibility, mindfulness, and ability to live according to personal values. These positive changes lasted for months and strongly correlated with reduced depression symptoms, suggesting that increased psychological adaptability may be key to psilocybin's therapeutic benefits.
Abstract
Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric condi...
Exploring U.K. cancer doctors’ attitudes toward psilocybin-assisted psychotherapy for cancer-related distress
OpenAlex – September 18, 2024
Summary
Oncologists show surprising openness to integrating novel interventions for cancer-related psychological distress. Interviews with nine oncologists in England revealed positive attitudes towards psilocybin-assisted psychotherapy. This development, bridging Psychology, Psychiatry, and Medicine, highlights a growing acceptance of Psychedelics and Drug Studies within clinical psychology. While embracing complementary and alternative medicine studies, they stressed safety, potential drug interactions, and the need for a psychotherapist to tailor approaches for diverse patient backgrounds, ensuring effective distress management.
Abstract
Abstract Background A diagnosis of cancer is often associated with significant psychological distress. Current approaches to cancer-related distres...
Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
Frontiers in Pharmacology – February 20, 2018
Summary
Psilocybin, a powerful hallucinogen, can profoundly shift perceptions for individuals battling addiction. Qualitative research on three participants undergoing psilocybin-assisted psychotherapy for alcohol use disorder revealed vivid, memorable moments. These experiences altered self-perception and relationship with alcohol, fostering feelings of catharsis and increased mindfulness. This clinical psychology approach, rooted in psychiatry and drug studies, suggests psilocybin's influence on behavior, demonstrating its potential in addiction psychology, as this alkaloid elicits variable yet deeply personal therapeutic experiences.
Abstract
After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a sm...
Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy
Frontiers in Pharmacology – April 03, 2018
Summary
A compelling finding in Clinical Psychology reveals psilocybin, a unique hallucinogen, offers profound relief for severe anxiety. In a trial involving 29 cancer patients, single-dose psilocybin (0.3 mg/kg) alongside a psychotherapist significantly reduced anxiety and depression. Thematic analysis of four participants highlighted personalized experiences, often addressing death anxiety and past trauma. This demonstrates the potential of Psychedelics and Drug Studies as Complementary and Alternative Medicine Studies, impacting Psychiatry and Psychology through Chemical synthesis and alkaloids in Medicine.
Abstract
A growing body of evidence shows that existential and spiritual well-being in cancer patients is associated with better medical outcomes, improved ...
Improving access to psilocybin-assisted therapy: barriers, challenges, and recommendations
Frontiers in Public Health – January 29, 2026
Summary
Approximately 80% of end-stage cancer patients report sustained symptom improvement after psilocybin-assisted therapy (PAT), a striking contrast to conventional antidepressant treatments. This innovative intervention combines psilocybin with structured psychological support, addressing existential distress often faced by terminally ill individuals. Despite its efficacy, access remains severely limited; between 2022 and 2024, only 318 of 471 applications for psilocybin use were approved in Canada. Advocates emphasize the urgent need for regulatory reform to improve access, particularly for marginalized populations facing systemic barriers to care.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention that combines the administration of psilocybin with structured psychological support ...
A double-edged sword: Insights from practitioners on the short and long-term negative effects of psilocybin-assisted psychological interventions
Journal of Psychedelic Studies – April 02, 2024
Summary
While psilocybin-assisted psychological interventions show promise, potential negative effects exist. Interviews with eight psychotherapists revealed three short-term challenges, including difficult self-experiences during dosing, and four long-term issues, such as client destabilization and adaptation difficulties. These findings in Psychedelics and Drug Studies highlight the multifaceted risks of such psychotherapy techniques. Thorough pre-intervention assessment and post-intervention support are crucial for safety in this emerging field of Psychology. Understanding these effects over the long term is vital for ethical applications.
Abstract
Abstract Background and aims Interest in psychedelic research has grown significantly in recent years and the naturally derived substance psilocybi...
Systematic study of Panaeolus (Agaricales, Galeropsidaceae) sensu lato and psilocybin-producing traits of species from China.
IMA fungus – January 01, 2026
Summary
Two species of psychedelic fungi, including a newly identified one (P. subfoenisecii), are confirmed psilocybin producers. This clarifies the classification of the Panaeolus group of hallucinogenic mushrooms, often found in pastures and forests, within the Agaricineae order. A comprehensive analysis, testing 14 species, establishes them as their own distinct family, Galeropsidaceae. This taxonomic revision proposes one new subgenus and eight new species, refining our understanding of these fascinating fungi and their evolutionary history.
Abstract
Panaeolus sensu lato is a group of hallucinogenic mushrooms commonly found on dung, in pasture areas, grasslands, and forests. Previous studies ind...
Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model
Psychological Medicine – June 02, 2023
Summary
Psilocybin, a potent hallucinogen, delivers the highest quality-adjusted life years (0.310) for severe depression, surpassing conventional medicine (0.278) or psychotherapy (0.283). While initial healthcare costs for psilocybin-assisted therapy ranged from £6132-£7652, this novel approach in Psychiatry and Psychology shows promising economics for depression. When psychotherapist support costs were halved and the chemically synthesized psilocybin price was £400-£800, this psychedelic medicine became cost-effective. This positions it as a significant complementary alternative in drug studies.
Abstract
Abstract Background: There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper ...
Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.
Psychological medicine – December 01, 2023
Summary
Psilocybin-assisted therapy shows promising cost-effectiveness in treating severe depression, delivering better quality-of-life outcomes than traditional treatments. Decision analysis reveals that while initial costs are higher, PAP leads to superior health improvements. When combined with reduced therapy support and optimized pricing, this treatment approach proves more economically viable than standard options for TRD.
Abstract
There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-eff...
Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts
Drug and Alcohol Dependence – November 01, 2015
Summary
Psilocybin treatment achieved 82% smoking abstinence in 11 participants at 30 months (91% at 6 months), with 73% follow-up. This highlights **Neuroscience**, **Biology**, **Cell biology**, **Chemistry** in **Psychedelics and Drug Studies**, exploring **receptor** influence on **dopamine**, **norepinephrine** on **axons**. Mechanisms involving **endocannabinoid system**, **cannabinoid receptor** (e.g., **2-Arachidonoylglycerol**), **tyrosine hydroxylase** via **immunoelectron microscopy** inform **Neurotransmitter Receptor Influence on Behavior** and **Cannabis and Cannabinoid Research**.
Abstract
Aims: We assessed long-term (>12 months) outcomes of psilocybin-facilitated smoking cessation, and qualitatively analyzed participants’ accounts to...
Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery
Therapeutic Advances in Psychopharmacology – January 01, 2024
Summary
A striking 61.2% of athletes would engage in psilocybin-assisted therapy for concussion recovery, with 71.1% of staff supporting it. An online survey of 175 individuals (85 athletes, 90 staff) revealed psychedelics were the third most used substance among athletes (35.8%) in the past year. This suggests the sports community, from a clinical psychology perspective, may be receptive to this hallucinogen for managing mood and cognition issues following concussions. Attitudes and knowledge of psilocybin, a naturally occurring alkaloid, predicted this willingness, hinting at its potential in medicine for conditions like depression.
Abstract
Background: Psychedelics are receiving growing interest among clinical researchers for their effects on mood and cognition. Psilocybin is one of th...
Comprehensive analysis of 42 psilocybin-producing fungal strains reveals metabolite diversity and species-specific clusters.
Scientific reports – April 22, 2025
Summary
Scientists have discovered that different magic mushroom species produce unique chemical fingerprints. Using advanced fungal extraction and liquid chromatography, researchers analyzed 42 strains of psilocybin-producing fungi, revealing distinct metabolic patterns. Beyond psilocybin, each species creates its own signature blend of compounds. The study also developed a method to mimic how our bodies process these substances through dephosphorylation.
Abstract
Psilocybin-producing fungi have garnered attention due to accumulating evidence regarding the therapeutic potential of their principal component ps...
Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use
Frontiers in Psychiatry – December 06, 2024
Summary
A 36-year-old daily Methamphetamine user achieved three months of abstinence and improved mental health following a single session of Psilocybin-assisted psychotherapy. This promising finding from a clinical trial in Psychiatry highlights the potential of this hallucinogen. As a field within Psychedelics and Drug Studies, the pharmacology of Psilocybin, a compound from chemical synthesis and alkaloids, suggests its Neurotransmitter Receptor Influence on Behavior could revolutionize addiction medicine. A psychotherapist guided the patient's psychology, demonstrating a novel approach.
Abstract
Methamphetamine (MA) dependence leads to severe physical and psychological issues. Current treatments, including psychosocial therapies and residen...
Psilocybin-Assisted Psychotherapy in Palliative Care
Oxford University Press eBooks – December 01, 2022
Summary
Psilocybin-assisted psychotherapy is re-emerging as a powerful psychological intervention for profound end-of-life distress. Despite advances in palliative care medicine, psychiatric and existential anguish persist, often unaddressed. Contemporary research in Psychiatry and Psychology is now examining psilocybin, delivered by a psychotherapist, to alleviate this suffering. Building on earlier Psychedelics and Drug Studies, this approach, encompassing Chemical synthesis and alkaloids and Complementary and Alternative Medicine Studies, offers a potential paradigm shift. It explores safety and efficacy data to transform end-of-life well-being.
Abstract
Abstract Following a decades-long hiatus and building on an innovative research model first developed from the 1960s to 1970s utilizing psychedelic...
Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy
Journal of Psychedelic Studies – August 21, 2023
Summary
Young adults are largely open to psilocybin-assisted therapy, challenging its historical taboo. An online survey of 118 Australian young adults via computer-assisted web interviewing revealed positive attitudes towards this hallucinogen's therapeutic potential. Individuals more open to new experiences and those with prior recreational drug use—including cannabis or other psychedelics like Lysergic acid diethylamide—showed greater support for psilocybin's safety, legality, and research in clinical psychology and psychiatry. This suggests a shifting public perception, moving psilocybin from a stigmatized drug to a promising tool in psychology, informed by Psychedelics and Drug Studies.
Abstract
Abstract Background Psilocybin, the psychoactive compound in magic mushrooms, is increasingly discussed in terms of its psychotherapeutic potential...
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
OpenAlex – January 01, 2026
Summary
Remarkably, a single 25 mg psilocybin dose, integrated with Acceptance and Commitment Therapy (a form of cognitive behavioral therapy), reduced binge eating frequency in all five adults with Binge-eating disorder over 14 weeks. This promising development in clinical psychology and psychiatry offers a new context for treating eating disorders. Participants reported improved anxiety and cognitive flexibility, with three (60%) also showing reduced BMI and no serious adverse effects. This medicine appears to enhance cognition and quality of life, potentially aiding relapse prevention for severe binge eating.
Abstract
Abstract Binge Eating Disorder (BED) is the most prevalent eating disorder and is associated with psychiatric comorbidities, health impairments, an...
Intentions, Spirituality, Set, and Setting Are Associated with Mystical Experiences in Psilocybin-Assisted Therapy
Psychedelic Medicine – January 12, 2026
Summary
Profound mystical experiences in psychedelic therapy for alcohol use disorder are strongly linked to a person's mindset and the treatment context. Twenty adults undergoing psilocybin-assisted therapy showed spirituality correlating highly with mystical intensity (r=0.76) in the first session, with intensity increasing by the second. Spiritual intentions also strongly connected (r=0.71). A positive mindset (r=0.52) and perceived positive setting (r=0.46) also predicted these intense religious experiences. This clinical psychology insight suggests how a psychotherapist might optimize preparation for psychedelic sessions.
Abstract
Objective: Emerging evidence suggests that mystical experiences mediate the therapeutic effects of psychedelic-assisted therapy. The current study ...
Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD
BMJ Open – May 01, 2023
Summary
Psilocybin-assisted therapy shows significant promise for severe PTSD, especially in US Military Veterans. A new open-label clinical trial, part of broader psychedelics and drug studies, will rigorously test this alternative medicine. This psychiatry protocol involves 15 veterans receiving two psilocybin doses (15 mg and 25 mg) alongside psychotherapist-led sessions. This crucial proof of concept aims to establish safety and efficacy, potentially integrating psilocybin into mainstream medicine for mental health challenges.
Abstract
Introduction Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-trau...
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
JAMA Psychiatry – August 24, 2022
Summary
Psilocybin dramatically reduced heavy drinking days for individuals with alcohol use disorder. In a randomized controlled trial of 93 participants, those receiving psilocybin, an alkaloid medicine, with psychotherapy reported 9.7% heavy drinking days over 32 weeks. This contrasted with 23.6% for the diphenhydramine placebo group, a 13.9% difference. This hallucinogen's influence on neurotransmitter receptors offers promise in psychiatry for relapse prevention, representing a significant step in psychology-informed psychedelics and drug studies.
Abstract
Importance Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin r...
Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms
OpenAlex – October 23, 2023
Summary
Norbaeocystin, a tryptamine, shows therapeutic promise without causing hallucinations. Pharmacology studies explored tryptamines, chemically similar to psilocybin, a known hallucinogen. While all compounds were metabolized similarly, only psilocybin induced head twitches in rats, indicating its psychedelic effects. Crucially, norbaeocystin, like psilocybin, improved antidepressant-like outcomes. This work in drug studies suggests chemical synthesis of specific alkaloids, relevant to tryptophan and brain disorders, could yield benefits without the full psychedelic experience seen with MDMA or other hallucinogens.
Abstract
ABSTRACT Demand for more efficacious antidepressants, particularly those with a rapid onset of action, has resulted in a reevaluation of psychedeli...
Psilocybin-induced stimulus control in the rat.
Pharmacology, biochemistry, and behavior – October 01, 2007
Summary
Rats trained to recognize psilocybin revealed its unique brain effects involve a complex interplay of receptors. The 5-HT2A receptor plays a prominent role in mediating psilocybin's distinct internal signal, yet it's not the sole factor. Other hallucinogens like LSD and psilocin produced similar responses, often blocked by 5-HT2A antagonists. Significantly, 5-HT1A receptors, active with some related compounds, were not involved in psilocybin's specific effects. This advances our understanding of psilocybin's precise mechanisms.
Abstract
Although psilocybin has been trained in the rat as a discriminative stimulus, little is known of the pharmacological receptors essential for stimul...
Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy
BMJ Supportive & Palliative Care – November 03, 2025
Summary
Terminally ill hospice patients experienced a significant 8.8-point reduction in demoralization scores after psilocybin-assisted therapy. Ten individuals received a single 25 mg psilocybin dose, demonstrating the intervention's feasibility and safety. It was well tolerated, with no serious adverse events, even amidst ongoing clinical decline. Participants reported profound grief and peace-related themes. Six of the ten patients rated the treatment favorably, suggesting a promising approach for integrating this therapy into end-of-life care to provide profound emotional support.
Abstract
Objectives To assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy (PAT) for demoralisation in terminally ill pat...
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Journal of Psychopharmacology – March 20, 2023
Summary
Psilocybin, a hallucinogen, demonstrated significant antidepressant effects for major depressive disorder. In a clinical psychology study, 19 individuals received placebo then 15 received psilocybin dosing (0.3 mg/kg); response rates reached 66.7% and remission 46.7%. While both conditions improved anxiety, psilocybin’s antidepressant effect sizes (d′ = 1.02–2.27) surpassed placebo’s (d′ = 0.65–0.99). This pharmacology research in psychiatry and medicine, exploring psychedelics and drug studies, underscores psilocybin's potential. Its unique chemical synthesis and role in complementary medicine approaches warrant further study.
Abstract
Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects f...
The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)
OpenAlex – August 13, 2020
Summary
A pioneering Yale manual is set to revolutionize Major Depressive Disorder treatment, offering a structured approach for psilocybin-assisted therapy. This multimodal therapy, integrating Acceptance and Commitment Therapy, guides psychotherapists in applying psilocybin—a powerful alkaloid often chemically synthesized—to address the complex psychology of depression. Building on promising early trials where over 65% of participants experienced significant symptom reduction, the manual provides a consistent framework for medicine and psychiatry. This development in psychedelics and drug studies aims to standardize care, potentially transforming mental health outcomes.
Abstract
The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider re...
High-Performance Liquid Chromatography Analysis of Psilocybin-Containing Mushrooms: Key Considerations and Insights
OpenAlex – October 26, 2023
Summary
Unlocking the intricate chemistry of psilocybin-containing mushrooms is now more precise. New insights into High-performance liquid chromatography (HPLC) analysis, crucial for Psychedelics and Drug Studies, offer a key to understanding these compounds. Experts refined chromatography methods, analyzing over 150 unique mushroom samples. This precision helps differentiate beneficial alkaloids from toxic substances, like those requiring Silymarin for mushroom poisoning. The advancements, vital for chemical synthesis, reveal the MAGIC in these fungi, achieving 99% accuracy in identifying psilocybin, pushing the boundaries of chemical analysis.
Abstract
HPLC analysis of psilocybin-containing mushrooms is a complex process that requires careful attention to detail. In this scientific summary, Doma N...
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors
Journal of Psychopharmacology – October 11, 2017
Summary
High-dose psilocybin, a potent hallucinogen, can foster lasting positive changes in human psychology. A trial with 75 participants showed that individuals receiving high-dose psilocybin (20 and 30 mg/70 kg) alongside meditation practices experienced significant trait-level increases in prosocial behavior, gratitude, and life meaning six months later. These enduring shifts, relevant to clinical psychology, were linked to mystical-type experiences and spiritual practices. The findings highlight psilocybin's potential for enhancing spirituality.
Abstract
Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduri...
Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report
Frontiers in Psychiatry – July 16, 2024
Summary
Strikingly, a single patient with major depressive disorder safely received the hallucinogen Psilocybin, an alkaloid often produced by chemical synthesis, alongside two serotonergic antidepressants, duloxetine and vortioxetine. This challenges conventional psychiatry that mandates antidepressant discontinuation before psychedelics. Psilocybin medicine was well-tolerated; mild headaches were the only adverse effect. However, discontinuing duloxetine worsened his anxiety, underscoring the vital neurotransmitter receptor influence on behavior. This suggests concurrent antidepressant drug studies, possibly including mirtazapine, could enhance treatment accessibility in psychology, avoiding unnecessary discontinuation risks.
Abstract
Psilocybin has reemerged as a promising treatment for difficult-to-treat depression (DTD). Although there is limited evidence regarding interaction...
Psilocybin-assisted therapy and HIV-related shame
Scientific Reports – August 02, 2024
Summary
Psilocybin-assisted therapy significantly reduced HIV-related shame, a major mental health barrier. In a pilot clinical trial of 12 participants, psilocybin-assisted group therapy led to a large decrease in shame (median change of -5.5 points, effect size r = -0.75) over three months. This offers a new avenue for psychiatry and clinical psychology, as conventional medicine struggles with HIV-related shame, which often leads to increased drug use and sexual risk. While promising for HIV care, two participants experienced increased sexual abuse-related shame, highlighting careful psychotherapist consideration in psychedelics and drug studies.
Abstract
Abstract As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of incr...
Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
BMJ Open – October 01, 2022
Summary
Could psilocybin offer a breakthrough in psychiatry for alcohol use disorder? A new double-blinded, randomized controlled clinical trial will investigate psilocybin-assisted therapy versus placebo. Ninety patients with alcohol dependence will receive a single dose under a strict protocol, aiming to reduce heavy drinking days over 12 weeks. This medicine, a psychedelic alkaloid, is being rigorously tested to establish its efficacy, examining total alcohol consumption and objective biomarkers. This contributes to vital psychedelics and drug studies.
Abstract
Introduction Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is ...
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
Psychiatry research – November 01, 2023
Summary
Psychedelic-assisted therapy using psilocybin shows remarkable promise in treating mood disorders, with patients experiencing significant relief from depression symptoms. Analysis of 13 clinical trials revealed that people with major depressive disorder or depression related to life-threatening cancer showed substantial improvement after supervised psilocybin sessions, with many achieving remission.
Abstract
The aim of this review was to determine the effect of psilocybin on depressive symptoms in patients diagnosed with life-threatening illnesses or ma...
Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder
Psychedelic Medicine – November 25, 2024
Summary
The hallucinogen psilocybin, an alkaloid from chemical synthesis, significantly altered values in 48 patients with alcohol use disorder receiving psychotherapy. Among 93 participants, those given psilocybin increased "Conservation" values (e.g., security, tradition). Acute psychedelic experiences correlated with these shifts (r=0.31–0.34). However, these psychological changes were unrelated to alcohol consumption outcomes. This informs medicine, psychiatry, and pharmacology within psychedelics and drug studies, including cannabis and cannabinoid research, by detailing how such compounds impact personal psychology.
Abstract
Background: Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is b...
Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress
Frontiers in Psychiatry – April 18, 2024
Summary
Over half (51.6%) of 31 patients with incurable illnesses expressed interest in future psilocybin treatment, offering hope in palliative care. This hallucinogen, administered with a psychotherapist, may address existentialism and distress often associated with grief. While many show openness to experience this approach in medicine and psychology, concerns about exploitation and lack of trained providers persist. This area within Psychedelics and Drug Studies highlights diverse academic research themes, bridging clinical psychology and psychiatry with spiritual practices.
Abstract
Introduction Patients with incurable illnesses often experience existential distress, profoundly impacting their well-being. Current medical approa...
Dose–response relationships of psilocybin-induced subjective experiences in humans
Journal of Psychopharmacology – March 04, 2021
Summary
Psilocybin, a potent hallucinogen, significantly intensifies subjective experiences. A meta-analysis synthesizing data from numerous studies using standardized rating scales revealed that higher doses of this chemical synthesis alkaloid positively correlate with increased perceptual alterations and positive ego dissolution. Effects on challenging experiences were small and barely dose-dependent. This finding is crucial for medicine, psychiatry, and psychology, including clinical psychology and Psychedelics and Drug Studies, informing Complementary and Alternative Medicine Studies and broader inquiries, even beyond parapsychology.
Abstract
Background: Psilocybin is the psychoactive component in Psilocybe mushrooms (‘magic mushrooms’). Whether and how the quality of the psilocybin-indu...
Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations
Journal of Neuroscience – June 19, 2013
Summary
Psilocybin, a potent serotonergic hallucinogen, profoundly alters visual processing, leading to visual hallucinations. Neuroscience reveals this psychedelic's effects, derived from chemical synthesis and alkaloids, are driven by activating specific Serotonin 5-HT2A receptors. Administering 215 μg/kg Psilocybin strongly decreased brain activity related to visual stimulus processing. Crucially, pretreatment with 50 mg Ketanserin, a 5-HT2A receptor blocker, completely prevented these changes and the associated visual hallucinations. This illuminates the specific neurotransmitter receptor influence on behavior, offering insights for psychology and drug studies.
Abstract
Visual illusions and hallucinations are hallmarks of serotonergic hallucinogen-induced altered states of consciousness. Although the serotonergic h...
Psilocybin-assisted psychotherapy for treatment-resistant obsessive–compulsive disorder: protocol for an open-label pilot study
BJPsych Open – December 15, 2025
Summary
Up to 60% of individuals with Obsessive-Compulsive Disorder (OCD) don't improve with standard therapies. A 12-week trial is exploring psilocybin-assisted psychotherapy for these treatment-resistant cases. Ten adults will receive a single 25 mg dose of psilocybin alongside psychological support. This initiative will assess the intervention's safety, tolerability, and preliminary clinical effects, using tools like the Yale–Brown Obsessive–Compulsive Scale. Additionally, it will examine brain changes to understand how psilocybin might work. These preliminary findings will guide larger studies into this promising approach for severe OCD.
Abstract
Background Obsessive–compulsive disorder (OCD) is a debilitating mental disorder commonly treated with selective serotonin reuptake inhibitors, aty...
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles
OpenAlex – February 04, 2024
Summary
A single dose of psilocybin dramatically boosts behavioral flexibility. Neuroscience reveals this psychedelic compound, an alkaloid with Neurotransmitter Receptor Influence on Behavior, acutely suppresses fear-active neurons while later recruiting extinction-active neurons. Over a five-day fear extinction assay, this modulation of neural ensembles in the retrosplenial cortex predicts improved fear memory resolution. This mechanism, crucial for Cognitive psychology and Psychology, offers new avenues for Psychedelics and Drug Studies addressing cognitive inflexibility.
Abstract
Abstract The serotonin 2 receptor (5HT2R) agonist psilocybin displays rapid and persistent therapeutic efficacy across neuropsychiatric disorders c...
A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy
OpenAlex – April 19, 2023
Summary
Psilocybin, a naturally occurring alkaloid, appears physiologically safe, suggesting its potential in medicine. A clinical trial among 14 healthy individuals found no unexpected adverse effects from 25 mg. While vital signs like blood pressure (peaking at 145.93 systolic, 93.93 diastolic) and heart rate increased, these returned to normal as the drug's neurotransmitter receptor influence waned. Internal medicine specialists and cardiologists confirm such transient changes are well-tolerated. This supports focused screening for future psychedelic drug studies, avoiding extensive anesthesia-like monitoring. Participants also reported reduced depression symptoms.
Abstract
Abstract This Phase I trial aims to inform the development of safety protocols for psilocybin-assisted therapy. Psychedelics, including psilocybin,...
A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient
Clinical Psychopharmacology and Neuroscience – May 21, 2024
Summary
While Psilocybin shows promise as a medicine, a compelling case highlights its risks: one patient with depression, personality traits, and cannabis use developed psychosis, catatonia, and suicidality after months of heavy Psilocybin use. This potent hallucinogen, often studied in Psychedelics and Drug Studies, can trigger psychosis in predisposed individuals consuming high or repeated doses. This finding, crucial for Mental Health and Psychiatry, underscores the need for careful consideration in Psychology and Neuroscience. Understanding Psilocybin's effects, from chemical synthesis and alkaloids to clinical application, is vital for safe integration into modern Psychiatry.
Abstract
Psilocybin is gaining popularity as research shows potential benefits to those with anxiety, depression, and other mental health conditions. Indivi...
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial
Frontiers in Pain Research – March 18, 2025
Summary
Three out of five individuals with Fibromyalgia experienced significant symptom improvement after a pilot clinical trial involving psilocybin-assisted therapy. This open-label Medicine study explored Psilocybin's potential, showing large reductions in pain severity (d=-2.1) and sleep disturbance (d=-2.5). This approach, combining Psychology with Psychedelics and Drug Studies, represents a new direction in Mental Health and Psychiatry. Unlike traditional physical therapy, this Complementary and Alternative Medicine Studies clinical trial suggests a novel Fibromyalgia treatment.
Abstract
Introduction Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, an...
“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy
Psychedelic Medicine – October 08, 2025
Summary
Patients with cancer often confront profound existential questions, with 100% of participants in a psilocybin-assisted therapy trial noting transformative experiences. In interviews with 28 individuals, themes emerged highlighting how cancer deepens awareness of mortality and prompts a re-evaluation of priorities. Participants sought not just relief from depression but also new perspectives on existential concerns. The lasting impacts included enhanced meaning, agency, and connectedness, suggesting that group psychotherapy using psychedelics like psilocybin can play a crucial role in addressing existential suffering and fostering personal growth.
Abstract
Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to me...
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression
Journal of Psychopharmacology – July 01, 2025
Summary
For 31 individuals with treatment-resistant major depressive disorder, a single 25 mg dose of psilocybin, administered in a therapeutic context with a psychotherapist, yielded a greater antidepressant effect when accompanied by profound mystical experiences. This insight from clinical psychology and medicine suggests the subjective aspects of psychedelics, derived from an alkaloid, are crucial. While psilocybin influences neurotransmitter receptors, this link between mysticism and symptom relief was specific to the initial dosing. This highlights the unique role of such experiences in psychiatry for treating severe depression.
Abstract
Background: Psilocybin-assisted psychotherapy (PAP) is a promising treatment for various psychiatric disorders. However, the exact biological and p...
Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder
OpenAlex – July 18, 2025
Summary
Psilocybin, a psychedelic alkaloid, appears to alter the epigenome, potentially explaining its lasting benefits for psychiatric conditions like alcohol use disorder. In 40 patients, a genome-wide association study of DNA methylation revealed changes after a 25mg dose. One CpG site in TLE4 and altered RASGRP4 methylation showed an association with psilocybin treatment. These epigenetic shifts relate to neuroplasticity and immune functions, suggesting a biological basis for reduced drinking behavior and depressive symptoms, crucial for psychology and psychiatry.
Abstract
Abstract The serotonergic hallucinogen psilocybin has shown potential as a treatment for psychiatric conditions like alcohol use disorder (AUD) and...
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.
Nature neuroscience – June 01, 2025
Summary
A single dose of psilocybin can help reduce fear responses by rewiring brain circuits, according to groundbreaking research using mouse models. The compound works by simultaneously suppressing neurons associated with fear while activating those linked to fear extinction. This dual action in the brain's retrosplenial cortex leads to improved behavioral flexibility and reduced fearful responses.
Abstract
The psychedelic drug psilocybin demonstrates rapid and long-lasting efficacy across neuropsychiatric disorders that are characterized by behavioral...
Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy
Psychedelic Medicine – May 08, 2024
Summary
Establishing clear boundaries for therapeutic touch is critical in psilocybin-assisted therapy, a growing area in medicine and psychology. After two unexpected touch experiences across three initial group retreats in a clinical trial, psychotherapists refined guidelines for this potent hallucinogen. These updated protocols for psychedelics and drug studies now ensure safe, supportive haptic interactions, vital for effective psychotherapy techniques and applications. Such careful attention to facilitator behavior is paramount for participant well-being, especially when addressing sensitive topics like sexuality, and could be enhanced by future technology.
Abstract
For a new clinical trial testing a group retreat-based format of psilocybin-assisted therapy, our research team created an initial set of practice ...
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial
OpenAlex – November 04, 2024
Summary
A compelling new avenue for Fibromyalgia pain management emerges: five individuals undergoing Psilocybin-assisted therapy, guided by a psychotherapist, reported substantial improvements. This open-label, proof-of-concept clinical trial in Psychedelics and Drug Studies found participants experienced significant reductions in pain severity (d=-2.1) and sleep disturbance (d=-2.5) one month post-treatment. While 80% reported transient headaches, no serious adverse events occurred. This initial Medicine finding, blending psychology with Mental Health and Psychiatry, warrants controlled trials to further understand its efficacy beyond any Placebo Effect.
Abstract
Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Curr...
Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.
Drug safety – May 01, 2025
Summary
Analysis of 2,000+ firsthand psychedelic experiences reveals distinct patterns: mushroom users report more introspective, time-altering journeys, while LSD users describe cognitive shifts. Advanced AI analysis found mushroom experiences were rated more positively overall, particularly among male users. Common themes across both substances included emotional depth and sensory enhancement.
Abstract
Psychedelics are gaining attention for their therapeutic potential in modern and personalized medicine. Online forums such as Erowid provide valuab...
PsiConnect: A Multimodal Neuroimaging Study of Psilocybin-Induced Changes in Brain and Behaviour
OpenAlex – April 14, 2025
Summary
A major Neuroimaging effort is exploring how the hallucinogen psilocybin impacts the brain and mind. This comprehensive investigation, relevant to Psychology and Neuroscience, involves 62 participants receiving a 19 mg dose of psilocybin. Using advanced brain scans and behavioral measures, it examines changes during meditation, music, and movies. Half the cohort also completed an 8-week meditation program, offering unique insights into how psychedelics interact with mental training. This valuable resource for Drug Studies and Cognitive psychology tracks effects for up to one year.
Abstract
ABSTRACT PsiConnect is a large-scale neuroimaging study designed to investigate the neural and subjective effects of psilocybin using multimodal ne...
Network pharmacology and molecular simulation reveal the entourage effect mechanisms of psilocybin-producing mushrooms on the brain
Scientific Reports – February 14, 2026
Summary
Whole mushroom extracts containing psilocybin may offer enhanced therapeutic potential for psychiatric disorders, outperforming isolated psilocybin. In a comprehensive analysis involving 15 compounds, eight showed promising pharmacokinetic profiles. Network analysis identified 44 brain-localized proteins linked to neurological pathways, with strong docking scores to key targets like HTR2A and MAOA. Notably, several compounds formed stable interactions with HTR2A, mimicking serotonin binding. These findings emphasize the significance of multi-target interactions and lay the groundwork for exploring the synergistic effects of mushroom-derived compounds in treating neurodegenerative diseases.
Abstract
The therapeutic potential of psilocybin in treating psychiatric disorders has gained attention recently. While most research has focused on isolate...
[Acceptance of psilocybin-assisted therapy in German-speaking countries].
Der Nervenarzt – February 12, 2025
Summary
Public acceptance of psychedelic therapy is growing in German-speaking regions, with 1,456 surveyed participants showing optimism toward psilocybin-assisted therapy. Higher knowledge levels and personal experience with psychedelics predicted more positive attitudes. Notably, balanced education about both benefits and risks led to increased acceptance among mental health professionals and the public.
Abstract
Clinical studies with psilocybin in combination with psychotherapy show promising results for the treatment of various mental disorders; however, t...
US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022
Journal of the American College of Emergency Physicians Open – August 30, 2025
Summary
Psilocybin-related calls to poison control centers surged threefold between 2013 and 2022, with nearly all incidents occurring since 2019. This sharp rise involving the hallucinogen psilocybin, an alkaloid, stands out in Psychedelics and Drug Studies, as other substances didn't show a similar pattern. While overall numbers remain low, this trend highlights a growing need for vigilance in Forensic Toxicology and Drug Analysis. As interest in psilocybin's psychology and chemical synthesis grows, poison control centers are increasingly vital.
Abstract
From 2013 to 2022, there was a 3-fold increase in psilocybin-related PC encounters, nearly all of which occurred since 2019. A similar pattern was ...
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
PLoS ONE – March 14, 2024
Summary
A strong therapeutic alliance dramatically improves outcomes for major depressive disorder. In a randomized controlled trial of 24 adults, the bond with a psychotherapist strengthened moderately (an effect size of .43) after psilocybin sessions. A stronger initial alliance strongly predicted lower depression scores at 4 weeks (correlation -.65) and significantly at 12 months (correlation -.54). This clinical psychology intervention, a form of psychedelic medicine, highlights how the human element, even against a placebo, drives profound and lasting relief in psychiatry, proving vital for effective psychotherapy.
Abstract
We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial chang...